uu.seUppsala University Publications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Renal Effects of Levosimendan: A Consensus Report
Show others and affiliations
2013 (English)In: Cardiovascular Drugs and Therapy, ISSN 0920-3206, E-ISSN 1573-7241, Vol. 27, no 6, 581-590 p.Article, review/survey (Refereed) Published
Abstract [en]

Renal dysfunction is common in clinical settings in which cardiac function is compromised such as heart failure, cardiac surgery or sepsis, and is associated with high morbidity and mortality. Levosimendan is a calcium sensitizer and potassium channel opener used in the treatment of acute heart failure. This review describes the effects of the inodilator levosimendan on renal function. A panel of 25 scientists and clinicians from 15 European countries (Austria, Finland, France, Hungary, Germany, Greece, Italy, Portugal, the Netherlands, Slovenia, Spain, Sweden, Turkey, the United Kingdom, and Ukraine) convened and reached a consensus on the current interpretation of the renal effects of levosimendan described both in non-clinical research and in clinical study reports. Most reports on the effect of levosimendan indicate an improvement of renal function in heart failure, sepsis and cardiac surgery settings. However, caution should be applied as study designs differed from randomized, controlled studies to uncontrolled ones. Importantly, in the largest HF study (REVIVE I and II) no significant changes in the renal function were detected. As it regards the mechanism of action, the opening of mitochondrial K-ATP channels by levosimendan is involved through a preconditioning effect. There is a strong rationale for randomized controlled trials seeking beneficial renal effects of levosimendan. As an example, a study is shortly to commence to assess the role of levosimendan for the prevention of acute organ dysfunction in sepsis (LeoPARDS).

Place, publisher, year, edition, pages
2013. Vol. 27, no 6, 581-590 p.
Keyword [en]
Levosimendan, Renal dysfunction
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-213306DOI: 10.1007/s10557-013-6485-6ISI: 000327094600012OAI: oai:DiVA.org:uu-213306DiVA: diva2:682163
Available from: 2013-12-23 Created: 2013-12-20 Last updated: 2017-12-06Bibliographically approved

Open Access in DiVA

fulltext(274 kB)138 downloads
File information
File name FULLTEXT01.pdfFile size 274 kBChecksum SHA-512
c0014f1e5084fc551f85757cb3d989be2302e4f6491b14f9fb1460d5e405a35af1c133bb247a6507452398e109d6ba1d56ba36a09a6f4b1c5a40a21d2d3117e5
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Authority records BETA

Wikström, Gerhard

Search in DiVA

By author/editor
Wikström, Gerhard
By organisation
Cardiology
In the same journal
Cardiovascular Drugs and Therapy
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 138 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 397 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf